Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
Study sponsor: Arcutis Biotherapeutics, Inc. · ARQT
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-11-19Actual
Enrollment · participants408Actual
Source updated2024-06-11Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.